INTS vs LLY

Intensity Therapeutics (INTS) remains an extremely high-risk, high-reward clinical-stage oncology biotech. While recent full-year 2025 results reported (March 27, 2026) show a narrowed net loss and an extended cash runway to Q2 2027, alleviating immediate liquidity concerns, the core challenges persist. Early Phase 2 data for INT230-6 continues to show promise (75% disease control rate), and Swiss...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...